Skip to main content
Journal cover image

How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.

Publication ,  Journal Article
Gold, DT; Alexander, IM; Ettinger, MP
Published in: Ann Pharmacother
June 2006

OBJECTIVE: To review the evidence on adherence with bisphosphonates and evolving dosing strategies for osteoporosis treatment. DATA SOURCES: Articles were identified by searching MEDLINE (1975-December 2005) using the following terms: osteoporosis, postmenopausal, fracture, adherence, compliance, persistence, drug therapy, bisphosphonates, alendronate, risedronate, ibandronate, and zoledronate. Additional data included bibliographies from identified articles. STUDY SELECTION AND DATA EXTRACTION: All pertinent English-language articles that discussed adherence issues in patients with osteoporosis were included. Both those that reviewed overall issues of medication adherence in osteoporosis and those that focused specifically on adherence to bisphosphonates were included, as were articles that addressed strategies for overcoming nonadherence. DATA SYNTHESIS: Inadequate diagnosis and treatment of osteoporosis result in a higher risk of fractures than is necessary. Even patients who are diagnosed and beginning treatment often do not persist with their osteoporosis medication because they perceive their fracture risk to be low and, given the asymptomatic nature of osteoporosis, do not experience the benefit of symptom reduction after taking the drugs. Factors that affect adherence to osteoporosis therapy include drug costs, adverse effects, dosing frequency, disease education, patient follow-up, and patient involvement in treatment decisions. CONCLUSIONS: By considering and implementing strategies that can improve adherence and persistence, primary care providers and pharmacists (via counseling) may enhance long-term outcomes for patients with osteoporosis.

Duke Scholars

Published In

Ann Pharmacother

DOI

ISSN

1060-0280

Publication Date

June 2006

Volume

40

Issue

6

Start / End Page

1143 / 1150

Location

United States

Related Subject Headings

  • Pharmacology & Pharmacy
  • Patient Education as Topic
  • Patient Compliance
  • Osteoporosis, Postmenopausal
  • Osteoporosis
  • Middle Aged
  • Injections, Intravenous
  • Humans
  • Female
  • Diphosphonates
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gold, D. T., Alexander, I. M., & Ettinger, M. P. (2006). How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother, 40(6), 1143–1150. https://doi.org/10.1345/aph.1G534
Gold, Deborah T., Ivy M. Alexander, and Mark P. Ettinger. “How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.Ann Pharmacother 40, no. 6 (June 2006): 1143–50. https://doi.org/10.1345/aph.1G534.
Gold DT, Alexander IM, Ettinger MP. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother. 2006 Jun;40(6):1143–50.
Gold, Deborah T., et al. “How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.Ann Pharmacother, vol. 40, no. 6, June 2006, pp. 1143–50. Pubmed, doi:10.1345/aph.1G534.
Gold DT, Alexander IM, Ettinger MP. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother. 2006 Jun;40(6):1143–1150.
Journal cover image

Published In

Ann Pharmacother

DOI

ISSN

1060-0280

Publication Date

June 2006

Volume

40

Issue

6

Start / End Page

1143 / 1150

Location

United States

Related Subject Headings

  • Pharmacology & Pharmacy
  • Patient Education as Topic
  • Patient Compliance
  • Osteoporosis, Postmenopausal
  • Osteoporosis
  • Middle Aged
  • Injections, Intravenous
  • Humans
  • Female
  • Diphosphonates